Dr. Horn on Selecting Inhibitors for ALK+ NSCLC

Video

In Partnership With:

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses selecting the necessary inhibitor for patients with ALK-positive non-small cell lung cancer.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses selecting the necessary inhibitor for patients with ALK-positive non—small cell lung cancer (NSCLC).

Horn says that in terms of efficacy, alectinib (Alecensa) is more effective than crizotinib (Xalkori) in the frontline setting. Ceritinib (Zykadia) resulted in better responses than chemotherapy, which is expected when comparing a targeted agent and chemotherapy, she adds.

Data also showed that ceritinib is more toxic than alectinib, suggesting that physicians should choose the latter in the first-line setting. Over time, she says, mechanisms of resistance will also come into play when deciding between these ALK inhibitors.

Overall survival is the key to deciding which drugs to use, Horn concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD